Why Was PCOS Renamed? The Four Reasons Behind the Switch to PMOS

What changed in 2026

A global consensus process published in The Lancet in 2026 renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome.

The process was not a committee of six people picking a nicer word. Fifty-six academic, clinical and patient organisations took part. Iterative global surveys collected responses from 14,360 people with the condition and health professionals across every world region, then modified Delphi rounds and nominal group workshops narrowed the options against five stated principles: scientific accuracy, clarity, stigma avoidance, cultural appropriateness, and whether health systems could actually implement it.

Three words survived: polyendocrine, metabolic, ovarian. They were chosen to describe the systems the condition genuinely involves. Accuracy was explicitly prioritised over keeping the familiar PCOS acronym.

Why was the old name a problem?

The “cysts” are not cysts

This is the objection the consensus paper leads with: the term PCOS is inaccurate because it implies pathological ovarian cysts.

What an ultrasound actually shows in this condition is a high count of small antral follicles — immature egg-containing sacs that have stalled early rather than growing, releasing an egg and clearing. They are a normal ovarian structure present in excess, not growths, not tumours, and not the fluid-filled ovarian cysts that sometimes need surgery.

That distinction matters because the wrong mental image travels. In a 2014 survey of women with the condition and primary care physicians, 47% of the women named ovarian cysts as a key feature — a feature that is neither required for diagnosis nor, strictly, present.

You can be diagnosed without polycystic ovaries

Diagnosis has never required the thing the old name is built on. Under the Rotterdam-based criteria carried forward by the 2023 international guideline, you need two of three features: irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. Meet the first two and the scan is not needed at all.

The 2023 update went further and added anti-Müllerian hormone (AMH) as an alternative to ultrasound in adults. So a person can now be diagnosed without ever having their ovaries imaged — while carrying a diagnosis named after how their ovaries look. If that sounds circular, see the Rotterdam criteria for how the two-of-three rule works in practice.

The name hid the metabolic half

The 2023 guideline strengthened recognition of features that have nothing to do with ovaries: metabolic risk factors, cardiovascular disease, sleep apnoea, a very high prevalence of psychological features, and high-risk status in pregnancy.

The old name pointed at none of that, and the knowledge gap showed up in the data. In the international survey that fed the consensus, at least 20% of patients and health professionals did not recognise the association between the condition and non-alcoholic fatty liver disease, pregnancy complications, cardiovascular risk factors, or endometrial cancer.

Patients and doctors both said the name confused them

Support for a change was not manufactured. In 2014, 48% of women surveyed and 74% of primary care physicians called the name confusing. By the 2023 survey round, 85.6% of patients and 76.1% of health professionals agreed the name should change, with fewer than 27% endorsing any of the listed disadvantages. The terms “endocrine” and “metabolic” drew the highest support for inclusion in a replacement — 86.2% among patients in 2023.

The case for the change, in numbers

Does the rename change your diagnosis or treatment?

No. This is the part worth being unambiguous about at 11pm.

The consensus was explicit that implementation runs through a transition period, education, and alignment with health systems and disease classification. Expect to see both terms in use for years. A fuller side-by-side is in PCOS vs PMOS.

Does it change anything by phenotype?

Not clinically — but the new name fits some phenotypes far better than the old one did.

If you were diagnosed on irregular cycles plus high androgens without any scan finding, the word “polycystic” never described you at all. Same if your diagnosis rests on hyperandrogenism and polycystic morphology while your cycles are regular — the metabolic and endocrine wording is closer to what is actually happening.

For the insulin-resistant pattern, which is the most common, the word “metabolic” finally appears in the diagnosis instead of being something you had to go looking for. The phenotype categories themselves are untouched.

What the rename has not been shown to do

Here is the honest limit. The consensus argues the old name contributed to delayed diagnosis, fragmented care and stigma. That is a reasoned position, not a measured effect.

The delay it refers to is real and well documented: in a survey of 1,385 women, 33.6% waited more than two years for a diagnosis and 47.1% saw three or more health professionals before getting one. Only 35.2% were satisfied with how they were diagnosed, and 15.6% with the information they were given.

But no study has yet tested whether changing the name shortens that wait, because the name is months old. Anyone telling you the rename will fix diagnostic delay is ahead of the evidence. What the change does now is make the words accurate, which is a precondition for better care rather than a substitute for it.

What to do at your next appointment

One thing, not five.

The 2023 guideline recommends that everyone with this diagnosis is assessed for glycaemic status and cardiovascular risk factors regardless of BMI — the part of the condition the old name kept out of view. Ask when yours were last checked. If the answer is “never” or “years ago”, that is the conversation to have.

If you want the wording to take in with you, use telling your doctor about PMOS. Everything else in the diagnosis section still applies exactly as written — only the name on it moved.